Myomedin MBA proteins aid in the diagnosis of patients with non-small cell lung cancer
Fri May 10 15:29:00 CEST 2024
Fri May 10 15:29:17 CEST 2024 | Fri May 10 15:29:17 CEST 2024 - Fri May 10 15:29:17 CEST 2024
Research team of the Laboratory of Ligand Engineering with its collaborators from Palacky University Olomouc (UPOL) has recently reported on engineering of small PD-1 binding proteins named Myomedins MBA that benefit diagnosis of non-small cell lung carcinoma (NSCLC) patients in vitro and monitoring PD-1 positive cell populations in vivo using positron emission tomography (PET/CT).
Programmed cell death 1 (PD-1) receptor-expressing tumor-infiltrating T lymphocytes (TILs) as predictive biomarkers have been reported for clinical benefit to PD-1 blockade in cancer patients like advanced NSCLC. For a high efficacy and clinical response to ICI therapy, mapping PD-1 expression on TILs and scoring the tumor infiltration is necessary before a treatment strategy decision is made. Therefore, by harnessing the power of directed evolution, we have crafted a set of Myomedin β-sheet-derived small binding proteins, dubbed MBA ligands, specifically targeting PD-1. The best MBA ligands exhibit specific binding to human and murine PD-1, thus offering a promising avenue for selective in vitro diagnostics of tumor tissue biopsies and sensitivity for real-time mapping of PD-1+ populations in vivo by PET/CT imaging.
For more details klick here: https://rdcu.be/dG8UU
Více informací naleznete zde: https://rdcu.be/dG8UU